Table of Contents
ISRN Gastroenterology
Volume 2014, Article ID 595213, 9 pages
http://dx.doi.org/10.1155/2014/595213
Clinical Study

Role of Pentoxifylline and Sparfloxacin in Prophylaxis of Spontaneous Bacterial Peritonitis in Cirrhotic Patients

1Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt
2National Liver Institute, Menoufiya University, Shebeen El Kom 32111, Egypt

Received 17 January 2014; Accepted 19 February 2014; Published 6 March 2014

Academic Editors: L. Rodrigo, R. G. Romanelli, and W. Vogel

Copyright © 2014 Tarek Mohammed Mostafa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Rimola and M. Navasa, “Infections in liver disease,” in Oxford Textbook of Clinical Hepatology, J. Bircher, J. P. Benhamou, N. McIntyre, M. Rizzetto, and J. Rode’s, Eds., pp. 1861–1876, Oxford University Press, Oxford, UK, 2nd edition, 1999. View at Google Scholar
  2. J. Lata, O. Stiburek, and M. Kopacova, “Spontaneous bacterial peritonitis: a severe complication of liver cirrhosis,” World Journal of Gastroenterology, vol. 15, no. 44, pp. 5505–5510, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. B. A. Runyon, “Spontaneous bacterial peritonitis: an explosion of information,” Hepatology, vol. 8, no. 1, pp. 171–175, 1988. View at Google Scholar · View at Scopus
  4. L. Titó, A. Rimola, P. Gines, J. Llach, V. Arroyo, and J. Rodes, “Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors,” Hepatology, vol. 8, no. 1, pp. 27–31, 1988. View at Google Scholar · View at Scopus
  5. P. J. Thuluvath, S. Morss, and R. Thompson, “Spontaneous bacterial peritonitis—in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998,” The American Journal of Gastroenterology, vol. 96, no. 4, pp. 1232–1236, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Rimola, G. García-Tsao, M. Navasa et al., “Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document,” Journal of Hepatology, vol. 32, no. 1, pp. 142–153, 2000. View at Google Scholar · View at Scopus
  7. C. Guarner and G. Soriano, “Bacterial translocation and its consequences in patients with cirrhosis,” European Journal of Gastroenterology and Hepatology, vol. 17, no. 1, pp. 27–31, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. R. D. Berg and A. W. Garlington, “Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model,” Infection and Immunity, vol. 23, no. 2, pp. 403–411, 1979. View at Google Scholar · View at Scopus
  9. B. A. Runyon, S. Squier, and M. Borzio, “Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis,” Journal of Hepatology, vol. 21, no. 5, pp. 792–796, 1994. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Fernández, M. Navasa, J. Gómez et al., “Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis,” Hepatology, vol. 35, no. 1, pp. 140–148, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Ginès, P. Angeli, K. Lenz et al., “EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis,” Journal of Hepatology, vol. 53, no. 3, pp. 397–417, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Pestova, J. J. Millichap, G. A. Noskin, and L. R. Peterson, “Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones,” Journal of Antimicrobial Chemotherapy, vol. 45, no. 5, pp. 583–590, 2000. View at Google Scholar · View at Scopus
  13. D. C. Hooper, “Mechanisms of action and resistance of older and newer fluoroquinolones,” Clinical Infectious Diseases, vol. 31, supplement 2, pp. S24–S28, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Harada, A. Ishizaka, M. Yonemaru et al., “The effects of aminophylline and pentoxifylline on multiple organ damage after Escherichia coli sepsis,” The American Review of Respiratory Disease, vol. 140, no. 4, pp. 974–980, 1989. View at Google Scholar · View at Scopus
  15. G. E. Chalkiadakis, A. Kostakis, P. E. Karayannacos et al., “Pentoxifylline in the treatment of experimental peritonitis in rats,” Archives of Surgery, vol. 120, no. 10, pp. 1141–1144, 1985. View at Google Scholar · View at Scopus
  16. M. M. Schonharting and U. F. Schade, “The effect of pentoxifylline in septic shock—new pharmacologic aspects of an established drug,” Journal of Medicine, vol. 20, no. 1, pp. 97–105, 1989. View at Google Scholar · View at Scopus
  17. D.-Z. Xu, Q. Lu, R. Kubicka, and E. A. Deitch, “The effect of hypoxia/reoxygenation on the cellular function of intestinal epithelial cells,” The Journal of Trauma: Injury, Infection and Critical Care, vol. 46, no. 2, pp. 280–285, 1999. View at Google Scholar · View at Scopus
  18. F. Corradi, C. Brusasco, J. Fernández et al., “Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites,” Digestive and Liver Disease, vol. 44, no. 3, pp. 239–244, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. R. N. H. Pugh, I. M. Murray-Lyon, and J. L. Dawson, “Transection of the oesophagus for bleeding oesophageal varices,” The British Journal of Surgery, vol. 60, no. 8, pp. 646–649, 1973. View at Google Scholar · View at Scopus
  20. H. U. Bergmeyer, M. Hørder, and R. Rej, “International Federation of Clinical Chemistry (IFCC) scientific committee, analytical section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 2. IFCC method for aspartate aminotransferase (L-aspartate: 2-oxoglutarate aminotransferase, EC 2.6.1.1),” Journal of Clinical Chemistry and Clinical Biochemistry, vol. 24, no. 7, pp. 497–510, 1986. View at Google Scholar · View at Scopus
  21. H. U. Bergmeyer, M. Horder, and R. Rej, “International Federation of Clinical Chemistry (IFCC) scientific committee, analytical section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (L-alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2),” Journal of Clinical Chemistry and Clinical Biochemistry, vol. 24, no. 7, pp. 481–495, 1986. View at Google Scholar · View at Scopus
  22. B. T. Doumas, P. P. Kwok-Cheung, and B. W. Perry, “Candidate reference method for determination of total bilirubin in serum: development and validation,” Clinical Chemistry, vol. 31, no. 11, pp. 1779–1789, 1985. View at Google Scholar · View at Scopus
  23. B. T. Doumas, W. A. Watson, and H. G. Biggs, “Albumin standards and the measurement of serum albumin with bromcresol green,” Clinica Chimica Acta, vol. 31, no. 1, pp. 87–96, 1971. View at Google Scholar · View at Scopus
  24. A. J. Quick, “Quick on “Quick agglutination venostasis” bleeding time technique,” The Journal of Laboratory and Clinical Medicine, vol. 26, article 1812, 1973. View at Google Scholar
  25. A. J. Taylor and P. Vadgama, “Analytical reviews in clinical biochemistry: the estimation of urea,” Annals of Clinical Biochemistry, vol. 29, no. 3, pp. 245–264, 1992. View at Google Scholar · View at Scopus
  26. K. Spencer, “Analytical reviews in clinical biochemistry: the estimation of creatinine,” Annals of Clinical Biochemistry, vol. 23, no. 1, pp. 1–25, 1986. View at Google Scholar · View at Scopus
  27. R. F. Henry, D. C. Cannon, and J. W. Winklemen, Clinical Chemistry: Principles and Techniques, Harper and Row, Hagerstown, Md, USA, 2nd edition, 1974.
  28. G. Goldman, D. Soffer, L. Heller, D. Aderka, A. Lahat, and J. M. Klausner, “Tumour necrosis factor mediates bacterial translocation after haemorrhagic shock and endotoxaemia,” European Journal of Surgery, vol. 167, no. 4, pp. 299–304, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Fernández, M. Navasa, J. Gómez et al., “Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis,” Hepatology, vol. 35, no. 1, pp. 140–148, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Cholongitas, G. V. Papatheodoridis, A. Lahanas, A. Xanthaki, C. Kontou-Kastellanou, and A. J. Archimandritis, “Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis,” Liver International, vol. 25, no. 1, pp. 57–61, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Saleh, M. Mohammad, S. Mashallah et al., “Inhibition of DPP IV is a suggested mechanism of the immunomodulatory effects of sparfloxacin,” Scientific Research and Essays, vol. 7, no. 3, pp. 310–317, 2012. View at Google Scholar
  32. Y. Matsunaga, H. Miyazaki, N. Nomura, and M. Hashimoto, “Disposition and metabolism of [14C]sparfloxacin after repeated administration in the rat,” Arzneimittel-Forschung, vol. 41, no. 7, pp. 760–763, 1991. View at Google Scholar · View at Scopus
  33. M. Nadai, Y. L. Zhao, L. Wang et al., “Endotoxin impairs biliary transport of sparfloxacin and its glucuronide in rats,” European Journal of Pharmacology, vol. 432, no. 1, pp. 99–105, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. G. A. P. Nieuwenhuijzen, Y. Haskel, Q. Lu et al., “Macrophage elimination increases bacterial translocation and gut-origin septicemia but attenuates symptoms and mortality rate in a model of systemic inflammation,” Annals of Surgery, vol. 218, no. 6, pp. 791–799, 1993. View at Google Scholar · View at Scopus
  35. J. V. Reynolds, P. Murchan, H. P. Redmond et al., “Failure of macrophage activation in experimental obstructive jaundice: association with bacterial translocation,” The British Journal of Surgery, vol. 82, no. 4, pp. 534–538, 1995. View at Publisher · View at Google Scholar · View at Scopus
  36. X. Wang, R. Andersson, V. Soltesz, P. Leveau, and I. Ihse, “Gut origin sepsis, macrophage function, and oxygen extraction associated with acute pancreatitis in the rat,” World Journal of Surgery, vol. 20, no. 3, pp. 299–308, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Josaki, J. Contrino, J. Kristie, P. Krause, and D. L. Kreutzer, “Pentoxifylline-induced modulation of human leukocyte function in vitro,” The American Journal of Pathology, vol. 136, no. 3, pp. 623–630, 1990. View at Google Scholar · View at Scopus
  38. P. J. Krause, J. Kristie, W.-P. Wang et al., “Pentoxifylline enhancement of defective neutrophil function and host defense in neonatal mice,” The American Journal of Pathology, vol. 129, no. 2, pp. 217–222, 1987. View at Google Scholar · View at Scopus
  39. C. Wenisch, K. Zedtwitz-Liebenstein, B. Parschalk, and W. Graninger, “Effect of pentoxifylline in vitro on neutrophil reactive oxygen production and phagocytic ability assessed by flow cytometry,” Clinical Drug Investigation, vol. 13, no. 2, pp. 99–104, 1997. View at Google Scholar · View at Scopus
  40. U. F. Schade, “Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor,” Circulatory Shock, vol. 31, no. 2, pp. 171–181, 1990. View at Google Scholar · View at Scopus
  41. S. Heller, K. Weber, A. Heller, R. Urbaschek, and T. Koch, “Pentoxifylline improves bacterial clearance during hemorrhage and endotoxemia,” Critical Care Medicine, vol. 27, no. 4, pp. 756–763, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. V. K. Shukla, A. K. Ojha, M. Pandey, and B. L. Pandey, “Pentoxifylline in perforated peritonitis: results of a randomised, placebo controlled trial,” European Journal of Surgery, vol. 167, no. 8, pp. 622–624, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. D. Lebrec, D. Thabut, F. Oberti et al., “Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis,” Gastroenterology, vol. 138, no. 5, pp. 1755–1762, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Ernst, “Pentoxifylline for intermittent claudication—a critical review,” Angiology, vol. 45, no. 5, pp. 339–345, 1994. View at Google Scholar · View at Scopus
  45. E. Akriviadis, R. Botla, W. Briggs, S. Han, T. Reynolds, and O. Shakil, “Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial,” Gastroenterology, vol. 119, no. 6, pp. 1637–1648, 2000. View at Google Scholar · View at Scopus
  46. J. Han, P. Thompson, and B. Beutler, “Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway,” The Journal of Experimental Medicine, vol. 172, no. 1, pp. 391–394, 1990. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Navasa, A. Follo, X. Filella et al., “Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality,” Hepatology, vol. 27, no. 5, pp. 1227–1232, 1998. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Cooper, A. Mikhail, M. W. Lethbridge, D. M. Kemeny, and I. C. Macdougall, “Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure,” Journal of the American Society of Nephrology, vol. 15, no. 7, pp. 1877–1882, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Rames, J.-M. Poirier, F. LeCoz et al., “Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients,” Clinical Pharmacology and Therapeutics, vol. 47, no. 3, pp. 354–359, 1990. View at Google Scholar · View at Scopus
  50. P. Neuner, G. Klosner, E. Schauer et al., “Pentoxifylline in vivo down-regulates the release of IL-1β, IL-6, IL-8 and tumour necrosis factor-α by human peripheral blood mononuclear cells,” Immunology, vol. 83, no. 2, pp. 262–267, 1994. View at Google Scholar · View at Scopus
  51. F. Corradi, J. Fernandez, M. Navasa et al., “Pentoxifylline prevents Small Intestinal Bacterial Overgrowth (SIBO), Bacterial Translocation (BT), and Spontaneous Bacterial Peritonitis (SBP) in experimental cirrhosis,” Journal of Hepatology, vol. 40, supplement 1, p. 14, 2004. View at Google Scholar
  52. S. Bailly, M. Fay, Y. Roche, and M. A. Gougerot-Pocidalo, “Effects of quinolones on tumor necrosis factor production by human monocytes,” International Journal of Immunopharmacology, vol. 12, no. 1, pp. 31–36, 1990. View at Publisher · View at Google Scholar · View at Scopus